QIAGEN N.V. filings document the reporting of a Netherlands-based foreign private issuer with common shares traded under QGEN. Its Form 20-F and Form 6-K disclosures cover audited annual financial statements, U.S. GAAP quarterly reports, operating and financial review, market-risk disclosures, legal proceedings, risk factors and the use of adjusted non-GAAP measures.
The filing record also includes exhibits and current reports tied to QIAGEN’s molecular diagnostics and life sciences portfolio, including sample technologies, QuantiFERON, QIAstat-Dx, QIAcuity and QIAGEN Digital Insights. Other disclosures address capital-structure actions such as a synthetic share repurchase and reverse stock split, material agreements, governance matters, exchange-listing registration notices and shareholder-facing corporate updates.
Wellington Management Group and affiliates report a 6.5% beneficial ownership stake in Qiagen N.V. common stock on Schedule 13G/A (Amendment No. 3). The group reports beneficial ownership of 14,137,799 shares as of the event date, with all voting and dispositive power held on a shared basis.
Within the complex, Wellington Management Company LLP reports shared voting power over 12,155,318 shares and shared dispositive power over 12,416,628 shares, representing 5.7% of the class. The filing states that the securities are owned of record by clients of Wellington investment advisers and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Qiagen.
BlackRock, Inc. reports owning 20,678,987 shares of QIAGEN N.V. common stock, representing 10.0% of the class as of January 31, 2026. BlackRock has sole voting power over 19,575,569 shares and sole dispositive power over the full 20,678,987 shares.
The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of QIAGEN. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares.
QIAGEN N.V. reported Q4 2025 and full-year 2025 results that modestly exceeded its own outlook and set guidance for 2026. Q4 net sales were $540 million, up 4% (1% at constant exchange rates), with adjusted diluted EPS of $0.62, ahead of guidance of about $0.60 CER.
For 2025, net sales reached $2.09 billion, up 6% (5% CER), at the high end of its 4–5% CER growth outlook. Adjusted diluted EPS was $2.40 CER, above the about $2.38 CER target, and the adjusted operating margin improved to 29.5% despite tariff and currency headwinds.
The company’s growth pillars generated $1.49 billion CER in 2025 sales with 8% CER growth, and it returned more than $1.1 billion to shareholders via synthetic share repurchases and a new cash dividend. For 2026, QIAGEN targets at least 5% CER sales growth, about $1.64 billion CER from growth pillars and adjusted diluted EPS of at least $2.50 CER.
QIAGEN N.V. is having its common shares removed from listing and registration on the New York Stock Exchange. The filing states that the Exchange has followed its own rules to strike this class of securities, and that the company has followed Exchange procedures and regulatory requirements for a voluntary withdrawal from listing and registration. This means QIAGEN’s common shares will no longer trade on the NYSE once the delisting process is effective, and trading would need to occur on other markets or venues if available.
QIAGEN N.V. submitted a Form 6-K noting that it has issued a press release with details on completing a synthetic share repurchase plan. This plan combines a direct capital repayment to shareholders with a reverse stock split, which together are intended to adjust the company’s share structure while returning capital.
The press release, dated December 18, 2025, is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed terms of the synthetic share repurchase and reverse stock split are provided in that accompanying document.
Wellington Management Group LLP filed an amended Schedule 13G reporting beneficial ownership in QIAGEN N.V. (QGEN) as of 09/30/2025. The filing lists 23,330,248 shares beneficially owned, representing 10.7% of the common stock.
The group reports 0 shares with sole voting or dispositive power, 19,132,735 with shared voting power, and 23,330,248 with shared dispositive power. One affiliated adviser, Wellington Management Company LLP, reports 6.9%. The securities are held for clients of Wellington-affiliated advisers, and the certification states they were acquired and are held in the ordinary course and not to change or influence control.
QIAGEN N.V. filed a Form 6-K summarizing several developments and furnishing related press releases as exhibits. The company announced a definitive agreement to fully acquire Parse Biosciences, a plan to return up to approximately $500 million to shareholders through a synthetic share repurchase, and that Thierry Bernard will step down as Chief Executive Officer and Managing Director.
QIAGEN also furnished a press release with unaudited financial results for the third quarter ended September 30, 2025. The filing reiterates the company’s use of non-GAAP and constant currency measures alongside GAAP results, noting reconciliations accompany the press release and that forward-looking non-GAAP reconciliations are not provided due to variability.
QIAGEN N.V. filed a Form 6-K as a foreign private issuer to provide its U.S. GAAP quarterly report for the three and six months ended June 30, 2025.
The quarterly report is furnished as Exhibit 99.1 and is incorporated by reference. The filing is signed on behalf of the company by Chief Financial Officer Roland Sackers.
Form 144 filed for QGEN reports a proposed sale of 25,000 common shares on the New York Stock Exchange with an aggregate market value of $1,220,000 and approximately 216,834,000 shares outstanding. The securities to be sold were acquired as restricted stock unit (RSU) awards on multiple dates in 2021 and 2022, with individual lots of 5,918; 5,247; 5,089; 4,253; and 4,493 shares. The filer states no securities were sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer. The planned transaction is scheduled for approximately 08/15/2025.